Considering Unmet Needs of Premenopausal Patients With Breast Cancer
Yeon Hee Park, MD, discusses the unmet needs in among premenopausal patients with metastatic breast cancer.
The Young-PEARL study (NCT02592746) compared exemestane (Aromasin) plus palbociclib (Ibrance) with ovarian function suppression (OFS) to capecitabine in premenopausal women with HR+/HER2– metastatic breast cancer. While the initial results showed improved progression-free survival (PFS) with the combination therapy, the updated analysis with longer follow-up did not demonstrate a significant difference in overall survival (OS) between the 2 groups.
Although the combination therapy extended PFS, it also led to a shorter time between the first and second disease progression compared to capecitabine. While the combination had more adverse effects, primarily neutropenia, both treatment options were generally manageable. In conclusion, the study found that while exemestane plus palbociclib with OFS improves PFS, it did not translate to a longer overall survival for these patients.
Here, Yeon Hee Park, MD, medical oncologist at the Samsung Medical Center in Seoul, South Korea, discusses the unmet needs in the patient population this study focused on.
Therapy Changes for Metastases and Toxicity Discussed in Breast Cancer
September 5th 2024During a Case-Based Roundtable® event, Ian Krop, MD, PhD, and event participants discussed how different types of metastases and treatment toxicity would affect therapy given to patients with triple-positive breast cancer in the second article of a 2-part series.
Read More
Breast Cancer Leans into the Decade of Antibody-Drug Conjugates, Experts Discuss
September 25th 2020In season 1, episode 3 of Targeted Talks, the importance of precision medicine in breast cancer, and how that vitally differs in community oncology compared with academic settings, is the topic of discussion.
Listen
